BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
September 15, 2016 08:37 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting
September 08, 2016 04:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company’s products and...
BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
September 06, 2016 16:05 ET
|
BioMarin Pharmaceutical Inc.
Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017 Additional 8 Months of Treatment (81-Week Data) Show Maintenance of Efficacy, Consistent with...